Eva Ramon-Gallegos

Dr. Eva Ramon-Gallegos

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
STSergio Andrés Torres-Pérez
Sergio Andrés Torres-Pérez
CTCindy Estefani Torres-Pérez
Cindy Estefani Torres-Pérez
MPMartha Pedraza-Escalona
Martha Pedraza-Escalona
SPSonia Mayra Pérez-Tapia
Sonia Mayra Pérez-Tapia
EREva Ramon-Gallegos
Eva Ramon-Gallegos
Nanoparticles (NPs) are novel platforms that can carry both cancer-targeting molecules and drugs to avoid severe side effects due to nonspecific drug delivery in standard chemotherapy treatments. Cancer cells are characterized by abnormal membranes, metabolic changes, the presence of lectin receptors, glucose transporters (GLUT) overexpression, and glycosylation of immune receptors of programmed death on cell surfaces. These characteristics have led to the development of several strategies for cancer therapy, including a large number of carbohydrate-modified NPs, which have become desirable for use in cell-selective drug delivery systems because they increase nanoparticle-cell interactions and uptake of carried drugs. Currently, the potential of NP glycosylation to enhance the safety and efficacy of carried therapeutic antitumor agents has been widely acknowledged, and much information is accumulating in this field. This review seeks to highlight recent advances in NP stabilization, toxicity reduction, and pharmacokinetic improvement and the promising potential of NP glycosylation from the perspective of molecular mechanisms described for drug delivery systems for cancer therapy. From preclinical proof-of-concept to demonstration of therapeutic value in the clinic, the challenges and opportunities presented by glycosylated NPs, with a focus on their applicability in the development of nanodrugs, are discussed in this review.

21 July 2017 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
PDF file
EAElizabeth Maldonado Alvarado
Elizabeth Maldonado Alvarado
MPMartha Olivia Osorio Peralta
Martha Olivia Osorio Peralta
AVAlejandra Moreno Vázquez
Alejandra Moreno Vázquez
LGLydia Alejandra Martínez Guzmán
Lydia Alejandra Martínez Guzmán
MPMaria Eugenia Melo Petrone
Maria Eugenia Melo Petrone
EREva Ramon-Gallegos
Eva Ramon-Gallegos

10 August 2012 in Sustainability
Verified
Journal Article
Open access
PDF file
CMCecilia E. Muñoz-Cadena
Cecilia E. Muñoz-Cadena
PLPedro Lina-Manjarrez
Pedro Lina-Manjarrez
IEIrma Estrada-Izquierdo
Irma Estrada-Izquierdo
EREva Ramon-Gallegos
Eva Ramon-Gallegos
Urban litter is generated by human societies everywhere. Some litter is recyclable waste. In this study, the acronym RMSW is used to refer to recyclable municipal solid waste generated in streets. Public attitude towards RMSW generation, generators’ perceptions, and quantification of RMSW in streets were examined in a Mexico City neighborhood, where litter presence causes major environmental problems affecting the population year after year. Interviews with neighborhood residents and item counts were carried out from 2010 to 2011. In all, 58% of interviewees reported generating RMSW at variable frequencies while 42% said they did not generate this kind of waste. Laziness, lack of vigilance by municipal authorities, no litter bins in streets, and imitation were the main causes identified by interviewees as reasons for littering. Potential litter generators may be of any age, educational level or income. Interviewees’ perception of RMSW generation was compared with item counts in the neighborhood studied.

3 February 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
AMAlejandro Martinez-Escobar
Alejandro Martinez-Escobar
BLBenjamín Luna-Callejas
Benjamín Luna-Callejas
EREva Ramon-Gallegos
Eva Ramon-Gallegos
Due to the high resistance that cancer has shown to conventional therapies, it is difficult to treat this disease, particularly in advanced stages. In recent decades, treatments have been improved, being more specific according to the characteristics of the tumor, becoming more effective, less toxic, and invasive. Cancer can be treated by the combination of surgery, radiation therapy, and/or drug administration, but therapies based on anticancer drugs are the main cancer treatment. Cancer drug development requires long-time preclinical and clinical studies and is not cost-effective. Drug repurposing is an alternative for cancer therapies development since it is faster, safer, easier, cheaper, and repurposed drugs do not have serious side effects. However, cancer is a complex, heterogeneous, and highly dynamic disease with multiple evolving molecular constituents. This tumor heterogeneity causes several resistance mechanisms in cancer therapies, mainly the target mutation. The CRISPR-dCas9-based artificial transcription factors (ATFs) could be used in cancer therapy due to their possibility to manipulate DNA to modify target genes, activate tumor suppressor genes, silence oncogenes, and tumor resistance mechanisms for targeted therapy. In addition, drug repurposing combined with the use of CRISPR-dCas9-based ATFs could be an alternative cancer treatment to reduce cancer mortality. The aim of this review is to describe the potential of the repurposed drugs combined with CRISPR-dCas9-based ATFs to improve the efficacy of cancer treatment, discussing the possible advantages and disadvantages.

16 September 2009 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AGArturo Gálvez-Rosas
Arturo Gálvez-Rosas
CGCelia González-Huerta
Celia González-Huerta
VBVerónica Borgonio-Cuadra
Verónica Borgonio-Cuadra
CDCarolina Duarte-Salazár
Carolina Duarte-Salazár
LLLorena Lara-Alvarado
Lorena Lara-Alvarado
AMAntonio Miranda-Duarte
Antonio Miranda-Duarte

1 March 2023 in Photochemistry and Photobiology
Verified
Journal Article
Closed access
MLMaría Teresa López‐Cárdenas
María Teresa López‐Cárdenas
AJAdriana Jiménez
Adriana Jiménez
AEAraceli Espinosa‐Montesinos
Araceli Espinosa‐Montesinos
EMElizabeth Maldonado‐Alvarado
Elizabeth Maldonado‐Alvarado
MOMartha Olivia Osorio‐Peralta
Martha Olivia Osorio‐Peralta
EREva Ramon-Gallegos
Eva Ramon-Gallegos